64502_Best of Cancer_KR.pdf (hubspotusercontent-na1.net)
Imvax got a write up after publishing their phase 1b results for patients with newly diagnosed Glioblastoma using their immunotherapy therapy.
https://www.imvax.com/wp-content/uploads/2023/11/Perez-Olle_CTIM-17_SNO_Ph1b_Poster.pdf
Positive write up and please correct me if I'm wrong but it looks like the all dose cohort only improved the standard of care for overall survival by 1.1 months.
Terrible disease. Hopefully we can bring some hope to a patient population in much need
Ann: 1st patient dosed in Phase 1b recurrent glioblastoma trial, page-55
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
-0.001(25.0%) |
Mkt cap ! $9.747M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.4¢ | 0.3¢ | $15.97K | 4.812M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 68 | 52690500 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 102587679 | 31 |
View Market Depth
| Last trade - 16.10pm 07/08/2025 (20 minute delay) ? |
| CHM (ASX) Chart |